1						
2	Treatment advantage in HBV/HIV coinfection compared to					
3	HBV monoinfection in a South African cohort					
4						
5	Tongai G Maponga <sup>1</sup> , Anna L McNaughton <sup>2</sup> , Marije Van Schalkwyk <sup>3</sup> , Susan Hugo <sup>3</sup> ,					
6	Chikezie Nwankwo <sup>4</sup> , Jantjie Taljaard <sup>3</sup> , Jolynne Mokaya <sup>2</sup> , David A Smith <sup>2</sup> ,					
7	Cloete van Vuuren <sup>5</sup> , Dominique Goedhals <sup>6</sup> , Shiraaz Gabriel <sup>4</sup> , Monique I Andersson <sup>1,7</sup> ,					
8	Wolfgang Preiser <sup>1</sup> , Christo van Rensburg <sup>4</sup> , Philippa C Matthews <sup>2,7,8</sup>					
9						
10	<sup>1</sup> Division of Medical Virology, Stellenbosch University / National Health Laboratory Service					
11	Tygerberg, Cape Town, South Africa					
12	<sup>2</sup> Nuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road,					
13	Oxford, UK					
14	<sup>3</sup> Division of Infectious Diseases, Department of Medicine, Stellenbosch University / Tygerberg					
15	Academic Hospital, Cape Town, South Africa					
16	<sup>4</sup> Division of Gastroenterology, Department of Medicine, Stellenbosch University / Tygerberg					
17	Academic Hospital, Cape Town, South Africa					
18	<sup>5</sup> Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences,					
19	University of the Free State, Bloemfontein, South Africa					
20	<sup>6</sup> Division of Virology, Universitas Academic Laboratories, National Health Laboratory					
21	Service/University of the Free State, Bloemfontein, South Africa					
22	<sup>7</sup> Department of Microbiology and Infectious Diseases, Oxford University Hospitals, John					
23	Radcliffe Hospital, Headington, Oxford, UK					
24	<sup>8</sup> NIHR British Research Council, John Radcliffe Hospital, Headington, Oxford, UK					
25						
26	* Corresponding author: philippa.matthews@ndm.ox.ac.uk					
27						
28	Keywords: hepatitis B virus, HBV, HIV, treatment, elimination, viral load, tenofovir, dolutegravir,					
29	hepatocellular carcinoma, South Africa, coinfection, sustainable development goals					
30						
31						
32						
33						

#### 34 ABSTRACT

35

36 **Objective:** Prompted by international targets for elimination of hepatitis B virus (HBV) 37 infection, we performed a cross-sectional observational study of adults with chronic HBV 38 (CHB) infection in South Africa, characterising individuals with HBV monoinfection vs. those 39 coinfected with HBV/HIV, to evaluate the impact of therapy and to guide improvements in 40 clinical care as guidelines for antiviral therapy change over time.

- 41 Design: We prospectively recruited 112 adults with CHB, of whom 38 (34%) had HIV
  42 coinfection, over one year in a university hospital in Cape Town, South Africa. We recorded
  43 cross-sectional demographic, clinical and laboratory data.
- 44 **Results:** Adults with HBV monoinfection were comparable to those with HBV/HIV coinfection 45 in terms of age, sex and body mass. HBeAg-positive status was more common among those 46 with coinfection (p=0.01). Compared to HBV/HIV coinfection, HBV monoinfected patients were 47 less likely to be on antiviral treatment and less likely to have been assessed by fibroscan 48 (p<0.0001 in each case); they were also more likely to have detectable HBV viraemia 49 (p=0.01), moderate/severe thrombocytopaenia (p=0.007), elevated bilirubin (p=0.002), and 50 APRI score >2 (p=0.02), suggesting underlying liver disease. Three cases of hepatocellular 51 carcinoma were reported, all in patients with HBV monoinfection. 52 **Conclusion:** Individuals with HBV monoinfection are disadvantaged in terms of clinical
- 53 assessment and appropriate antiviral therapy compared to those with HIV coinfection, 54 associated with relatively worse liver health. Enhanced advocacy, education, resources and 55 infrastructure are required to optimise interventions for CHB.

56

#### 58 **'SUMMARY BOX'**

#### 59 What is already known about this subject?

60 Chronic infection with hepatitis B virus (HBV) is the cause of a substantial burden of disease in 61 sub-Saharan Africa, with morbidity comparable to that caused by tuberculosis or malaria. 62 Rates of liver disease associated with HBV are rising, but international sustainable 63 development goals have set ambitious targets for elimination of the infection as a public health 64 threat by the year 2030. In many parts of southern Africa, HBV is co-endemic with HIV 65 infection. The conventional paradigm has been that the coinfection is associated with worse 66 outcomes from both infections. However, this accelerated pathology may be halted by the 67 introduction of antiviral therapy, with tenofovir being central to regimens for both HIV and HBV 68 infection. This agent suppresses viral replication, leading to improved outcomes in both HIV 69 and HBV infection, but certain questions remain to be considered, including its role in 70 coinfection, the risk of drug resistance and toxicity, and the impact of changing antiretroviral 71 regimens over time.

#### 72

#### 73 What are the new findings?

74 We have studied adults with CHB under review at a teaching hospital in South Africa, 75 reviewing clinical and laboratory data in the presence and absence of HIV coinfection. The 76 group with coinfection was statistically more likely to be HBeAg-positive, suggesting an 77 increased risk of accelerated liver disease. However, we show that the HBV monoinfected 78 group are in fact disadvantaged: they are less likely to be on antiviral therapy (even when 79 meeting treatment criteria), and therefore less likely to be virologically suppressed. 80 Furthermore, coinfected patients are less likely to undergo full clinical evaluation and are 81 characterised by increased rates of liver disease based on a range of markers including 82 platelet count, bilirubin and fibrosis scores. We found no evidence of nephrotoxicity in 83 association with the use of tenofovir. Thus, overall we show that the HBV monoinfected group 84 have worse liver outcomes in comparison to those with HBV/HIV coinfection. Those with HIV 85 coinfection have a therapeutic advantage, as a result of secure access to monitoring and 86 consistent provision of antiviral therapy, and there is no evidence of a risk of toxicity 87 associated with treatment.

88

#### 89 How might it impact on clinical practice in the foreseeable future?

90 Those with HBV monoinfection are vulnerable to evolving complications. We highlight the 91 importance of careful clinical surveillance of this group, the importance of early diagnosis and

investigation, and a low threshold for the introduction of antiviral therapy. As antiretroviral
therapy regimens change over time, with a move towards dolutegravir-based dual therapy,
there is a risk of HBV/HIV-infected patients losing access to tenofovir therapy. Our results
highlight the importance of maintaining tenofovir provision and scaling up treatment at a
population level in order to make progress towards 2030 elimination targets.

#### 98 INTRODUCTION

99 The burden of chronic infection with hepatitis B virus (HBV) in southern Africa is high, and in this 100 setting the distribution overlaps with populations in which HIV infection is endemic [1]. Due to 101 high rates of coinfection, and the overlap in antiviral regimens, there is a pressing need to 102 develop an enhanced understanding of the interplay between these infections, and to capitalise 103 on opportunities for deploying existing HIV infrastructure to improve HBV diagnosis, clinical care 104 and prevention. International sustainable development goals set a target for elimination of HBV 105 as a public health problem by the year 2030 [2]. Developing insights into the characteristics and 106 outcomes of chronic HBV (CHB) monoinfection and HBV/HIV coinfection will underpin improved 107 strategies for monitoring, prognostication, patient stratification and therapy. Changes in 108 recommendations for cART regimens for HIV infection should consider the individual and public 109 health impact of therapy on individuals who are co-infected with HBV, particularly in the co-110 endemic populations of sub-Saharan Africa.

111

112 A traditional paradigm suggests that individuals with HBV/HIV coinfection might have a worse 113 prognosis from chronic liver disease than those with HBV monoinfection, typically linked with 114 higher rates of HBeAg-positivity and higher viral loads [1,3], lower CD4+ T cell counts, 115 increased incidence of liver fibrosis [4] and hepatocellular carcinoma (HCC), higher rates of 116 vertical HBV transmission, and higher overall mortality [5]. However, this picture is not 117 consistent between populations (even within individual studies [6]) and the interplay between 118 viruses may be affected by specific characteristics of the host or viral population [7], and by 119 changes in treatment guidelines over time.

120

121 Lamivudine (3TC) and tenofovir (most commonly in the form of tenofovir disoproxil fumarate, 122 TDF) have established track records of safety and tolerability in both HIV and HBV infection. 123 Long-term 3TC use is hampered by a high rate of selection of resistance [8], while TDF is 124 favoured as the genetic barrier to resistance is high [9]. Following publication of the START trial 125 in 2015, HIV treatment is now initiated irrespective of clinical or immunological status [10]. This 126 practice is now enshrined in '90-90-90' targets, seeking to have 90% of cases diagnosed, 90% 127 of these on treatment, and 90% of these virologically suppressed [11]. TDF is one of the 128 recommended choices for the NRTI backbone of cART for HIV [12]; in South Africa, TDF is 129 used for first-line cART in combination with 3TC/EFV or FTC/EFV [13]. In second-line regimens, 130 TDF is commonly added to a protease inhibitor (PI) with a backbone of zidovudine (AZT)+3TC.

Thus the majority of HIV-positive individuals with HBV coinfection receive TDF as a componentof routine first or second-line therapy.

133

134 In contrast, for HBV monoinfection, TDF is prescribed only for a subset of patients, based on 135 algorithms that incorporate assessment of the patient (age and sex), virologic status (HBV DNA 136 viral load) and the presence of underlying fibrotic or inflammatory liver disease (ALT, 137 elastography score, ultrasound appearance, biopsy results) [14-16]. WHO targets for 2030 aim 138 for 90% of HBV cases to be diagnosed, and for 80% of those eligible for treatment to be 139 receiving it [17]. However, only a small minority of those living with CHB are currently aware of 140 their status [18], patient stratification and monitoring using laboratory and radiological 141 approaches is not accessible in many settings [18], and current assessment misses a high 142 proportion of patients who should be treated [19].

143

Recognising the need for improved characterisation of HBV infection, both alone and in combination with HIV coinfection, we have undertaken a cross-sectional analysis of adults with CHB in an urban cohort in South Africa. We set out to explore the differences between individuals with monoinfection and coinfection, and to compare rates and outcomes of antiviral therapy, with the aim of informing current and future therapeutic guidelines.

149

#### 150 **METHODS**

#### 151 Clinical cohort

We recruited adults with CHB infection, with or without HIV coinfection, attending routine clinical follow-up in hepatology and infectious diseases outpatient clinics at Tygerberg Hospital, a tertiary referral hospital in Cape Town. HIV clinics within the referral area are encouraged to send all patients diagnosed with HIV-HBV coinfection to the Tygerberg clinic for counselling and baseline investigations including clinical assessment, laboratory tests and elastography. Patients are followed at the clinic at intervals according to the baseline findings.

158

Cases were defined as being HBsAg-positive (typically over a period of >6 months of clinical follow up) and were recruited into a cross-sectional cohort (Oxford-South Africa Hepatitis Cohort, 'OxSA-Hep'), commencing July 2018. We here present the results of a planned interim analysis of data after 12 months of recruitment.

We recorded treatment with antiviral therapy at the time of recruitment to the study, routine clinical laboratory data (including serological markers of HBV infection, creatinine, liver function tests and platelet count), and documented elastography scores when the patient had been assessed by fibroscan. We recorded data in a LabKey database [20] using a unique pseudonymised patient ID number.

169

#### 170 Generation and analysis of laboratory data

Biochemical and serological data were generated on the Cobas 6000 series e601 module
analyzer (Roche Diagnostics GmbH, Germany). Platelet counts were obtained using the Advia
2120i analyzer (Siemens Healthcare Diagnostics Inc, USA). HIV and HBV viral loads were
measured using Cobas Ampliprep/Taqman tests (Roche Molecular Diagnostics, the
Netherlands).

176

The upper limit of normal (ULN) for ALT was 19 iu/ml for females and 30 iu/ml for males [16,21],
ULN for AST = 40 iu/ml, ULN for BR = 17 mmol/L. We calculated liver fibrosis scores, AST to

179 Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) as follows:

• APRI = (AST / ULN AST) / (Platelet count x 100)

• FIB-4 = (Age in years x AST) / (Platelet count \* √AST)

We used thresholds of FIB-4 >3.25 (97% specificity, and positive predictive value of 65% for
advanced liver fibrosis [22]), and APRI >2 (91% specific for cirrhosis [23,24]).

184

185 We measured renal function based on estimated glomerular filtration rate (eGFR) as follows:

186 • 186 x (creatinine (μmol/L)/88.4)<sup>-1.154</sup> x (age in years)<sup>-0.203</sup> x (0.742 if female) x (1.210 if black) [25].

188 Normal renal function is defined as  $eGFR \ge 90 \text{ ml/min/1.73m}^2$ . We grouped together individuals

with renal impairment, defined as chronic kidney disease (CKD) Stage II (eGFR 60-89 ml/min) or Stage III (eGFR 30-59 ml/min). We defined moderate/severe thrombocytopaenia as a platelet count  $<75 \times 10^3/\mu$ I [26].

192

#### 193 Elastography

Elastography to quantify liver stiffness (an assessment of inflammation and/or fibrosis) is not
undertaken consistently in this setting, but is performed in a subset of patients at the discretion
of the clinical team using the Fibroscan 402 (Echosens, Paris, France). Elastography scores are

not reliable in individuals with a high body mass index or during pregnancy, and would not be
undertaken in these circumstances. Due to the cross-sectional nature of the cohort, we
recorded elastography scores at a single time point only.

200

#### 201 *Treatment indications and outcomes*

We have referred to HBV treatment recommendations published by the UK National Institute for Clinical Excellence (NICE) [21], the European Association for the Study of the Liver (EASL) [15], and South African national guidelines [16]. All concur in advising tenofovir or entecavir as firstline options, and recommend that stratification for therapy should be based on laboratory parameters, on the presence and extent of existing liver disease assessed by imaging and/or biopsy, and on consideration of other individual clinical and demographic factors.

208

209 Due to resource constraints, liver biopsy is rarely undertaken in this setting and we have 210 primarily used laboratory parameters to assess treatment eligibility. South African guidelines 211 suggest consideration of therapy for individuals who are HBeAg-positive with HBV DNA 212 >20,000 IU/ml and ALT above ULN, or who are HBeAg-negative with HBV DNA >2,000 IU/ml 213 and ALT above ULN, with the aim of achieving durable suppression of HBV DNA to low or 214 undetectable levels and normalisation of ALT [16]. Individuals with HIV coinfection are routinely 215 treated with first line combined antiretroviral therapy (cART) that includes HBV-active agents 216 [13]. In practice in this setting, TDF is therefore first line therapy for CHB, both in the presence 217 and absence of HIV infection.

218

#### 219 Statistical analysis

We analysed data using GraphPad prism v 8.0.1. For continuous variables, we used Mann Whitney Test; for categorical variables we used Fisher's Exact Test. Linear regression was used to assess associations between two continuous variables. For multivariate analysis, we performed multivariate logistic regression using bayesglm function of the R package.

224

#### 225 *Ethics*

Ethics approval was provided by University of Oxford Tropical Research Ethics Committee (ref.
OXTREC 01-18) and Stellenbosch University Human Research Ethics Committee (HREC ref.
N17/01/013). All participants provided written valid informed consent. A STROBE statement to
support the quality of this observantional study is available (Suppl. Table 1)

#### 231 Patient and Public Involvement

Our teams run an active program of public engagement, with events taking place throughout the year in the UK and in South Africa. We have recently redesigned patient information sheets based on feedback from the clinics at recruitment sites, to improve clarity and accessibility of communication [27].

236

#### 237 RESULTS

#### 238 Representation of HBV monoinfection and HIV/HBV coinfection in an adult cohort

We recruited 112 adults with HBV infection (55% male), representing 74 adults with HBV monoinfection (66%) and 38 with HBV/HIV coinfection (34%) (Fig 1). The full metadata are available in Suppl. Table 2. Summary data for the cohort are presented in Table 1, showing a comparison of attributes of HBV monoinfection and HBV/HIV coinfection. Extended material are presented in Suppl. Table 3. Based on small numbers and borderline statistical significance at univariate level, we did not anticipate multivariate analysis to demonstrate many significant variables, but those that were significant are referenced in the footnotes to Tables 1 and 2.

246

The majority of participants were of South African origin (88%; Suppl. Fig 1). There was no significant difference in sex, age or body weight between the monoinfected and coinfected groups (p=0.24, 0.28, and 0.20 respectively; Table 1). HBeAg-positive status was significantly more common among individuals with HIV coinfection (34%) compared to HBV monoinfected individuals (12%); p=0.009; Fig 2A; Table 1.

252

#### 253 Antiviral therapy and virologic outcomes in HBV monoinfection vs HIV/HBV coinfection

254 Antiviral therapy and outcomes are shown in Fig 1 and Table 2. As anticipated, based on HIV 255 treatment guidelines [13], a significantly greater proportion of the coinfected group was on 256 antiviral therapy compared to the monoinfected group (97% vs. 49% respectively, p<0.0001; Fig 257 2B; also significant on multivariate analysis). Accordingly, HBV DNA was more likely to be 258 suppressed below the limit of detection in coinfected than monoinfected patients (57% vs 33%, 259 respectively; p=0.03; Fig 2C), and absolute values for HBV DNA viral load (VL) were also 260 significantly lower in the coinfected group than the monoinfected (p=0.049; Suppl Fig 2A). 261 Duration of antiviral therapy was recorded for 29 individuals with HBV monoinfection (median 29 262 months) and 27 individuals with HIV coinfection (median 37 months); p=0.1.

264 In the HBV/HIV coinfected group, 37/38 adults were on antiviral therapy that included HBV-265 active agents (TDF and/or 3TC); one patient was not on therapy. HIV VL data were available for 266 33/37, being undetectable in 21/33 (64%) and <1000 RNA copies/ml in 5/33 (15%). Overall, 267 suppression of HIV viraemia was associated with suppression of HBV viraemia (p=0.02; Fig 2D, 268 Suppl Fig 2B). However, among individuals with undetectable HIV VL, HBV DNA was still 269 detectable in 5/21 (24%). Among these, one was being treated with 3TC as the only HBV-active 270 agent, with HBV DNA VL 1.0 x 10<sup>5</sup> IU/ml. Suppression of HIV viraemia suggests adherence to 271 cART, and the high HBV viral load is therefore consistent with 3TC resistance. The other four 272 were receiving TDF-based combination therapy, making drug resistance a less likely 273 explanation for HBV viraemia (HBV VL 20-5444 IU/ml). Treatment start date was ≥15 months 274 prior to the date of recruitment (recorded in 3/5 cases), making it unlikely that HBV viraemia was 275 detectable because therapy had only recently been instituted.

276

#### 277 Proportion of untreated HBV monoinfected patients who meet treatment criteria

We reviewed the data for 36 HBV monoinfected individuals off therapy to determine the proportion of these who met treatment criteria. Using South African guidelines [16], 6/36 (17%) were treatment eligible (3/36 HBeAg-positive with HBV DNA >20,000 IU/ml plus 5/36 HBeAgnegative with HBV DNA >2,000 IU/ml, of whom 6/8 had ALT >ULN). Based on the European guidelines, 7/36 (19%) individuals would be eligible for therapy (HBV DNA >2,000 IU/ml and ALT >ULN) [15].

284

#### 285 Prevalence of liver disease: laboratory data

286 We assessed laboratory data and elastography scores as markers for underlying liver disease. 287 There was no significant difference in ALT or AST between monoinfected vs. coinfected 288 individuals (Suppl. Table 3). For BR, the proportion with an elevated value was higher in the 289 monoinfected than in the coinfected group (albeit not reaching statistical significance, p=0.08; 290 Fig 3A), but the absolute values were significantly higher in those with monoinfection (p=0.003; 291 Fig 3C). Thrombocytopaenia can be an indicator of chronic liver disease as a result of a variety 292 of mechanisms, including splenic sequestration and myelosuppression [26]. Strikingly, all the 293 individuals with moderate/severe thrombocytopaenia were in the HBV monoinfected group (Fig 294 3B,D) suggesting a subgroup of individuals with established liver disease. We calculated fibrosis

scores from laboratory data, finding a higher proportion of the HBV monoinfected group had
scores predictive of cirrhosis/fibrosis (for APRI: p=0.02, Fig 4A; for FIB-4: p=0.1, Fig 4B).
Despite no difference in median APRI or FIB-4 between monoinfected and coinfected groups, it
is striking that 12/14 individuals with elevated fibrosis scores were in the HBV monoinfected
group (Fig 4C, 4D).

300

#### 301 Prevalence of liver disease: elastography and clinical data

Only a small proportion of the cohort had elastography data (n=38/112, 34%). Individuals with HBV/HIV coinfection were more likely to be assessed by elastography, undertaken in 30/38 cases (79%) compared to only 8/74 (11%) of individuals with HBV monoinfection (p<0.0001; Table 1; also significant on multivariate analysis). Among 38 individuals with elastography data, there were slightly higher scores in the HBV monoinfected group compared to those with coinfection, although this did not reach statistical significance (median score 6.9 kPa vs 5.6 kPa, respectively; p=0.3; Table 1).

309

A greater proportion of the HBV monoinfected group had fibroscan scores that would meet criteria for treatment. A threshold of 6 kPa [21], was exceeded in 4/8 (50%) of monoinfected patients vs. 12/30 (40%) of coinfected patients; while the stringent threshold of 9kPa [15] was exceeded in 3/8 (38%) of monoinfected patients vs 4/30 (13%) coinfected patients. However, due to small numbers in each group, neither of these differences reached statistical significance (p=0.7 and p=0.1, respectively).

316

We reviewed clinical records for complications reported by specialist doctors in 106 cases. Among these, 18/106 (17%) had documented complications of HBV infection, including 17 cases of cirrhosis (16% prevalence) and 3 cases of HCC (3% prevalence); two patients had both cirrhosis and HCC. All HCC cases occurred in the context of HBV monoinfection. The prevalence of hepatic complications was almost twice as high in HBV monoinfection (14/68; 21%) compared to HBV/HIV coinfection (4/38; 11%), although this difference did not reach statistical significance due to small numbers in each group (p=0.3; Table 1).

324

#### 325 Evidence of renal dysfunction

Chronic kidney disease (CKD) can arise in association with HIV infection, and is also a potential
side effect of TDF therapy [28]. Therefore, we examined this cohort for the presence of CKD
based on calculation of eGFR, available for 99 individuals. CKD stage II or III was present in

329 31/99 (31%) of the cohort. However, we found no difference in rates of CKD between individuals 330 with HBV monoinfection vs HBV/HIV coinfection (CKD II/III present in 21/63 (33%) vs 10/36 331 (28%), respectively, p=0.7). There was no evidence of nephrotoxicity among those on TDF; 332 indeed there was a trend towards increased prevalence of CKD among the untreated group vs 333 those on antiviral treatment (CKD II/III present in 18/63 (29%) vs 13/32 (41%) respectively; 334 p=0.2).

335

#### 336 DISCUSSION

#### 337 Context and primary conclusions

338 Developing a detailed understanding of the characteristics of CHB, and the clinical interplay with 339 coendemic HIV, is important to drive forward improvements in care provision, with gains to be 340 made both for individuals populations. Although successful vaccination campaigns are well 341 established, modelling studies predict long timeframes to elimination [29,30], and programmes 342 to enhance diagnosis and treatment will therefore be crucial in the decade ahead.

343

344 The traditional paradigm suggests that patients with HBV/HIV coinfection may have worse 345 outcomes than those with HBV monoinfection, and we confirmed a significantly higher 346 prevalence of HBeAg-positive status in those with HIV coinfection. Despite this, our data 347 indicate that the monoinfected group is disadvantaged compared to those with coinfection, 348 evidenced by the significant association between monoinfection and lower rates of access to 349 appropriate clinical surveillance, lower rates of antiviral treatment (even among those who meet 350 treatment criteria), higher HBV viral loads, more established liver disease (hyperbilirubinaemia, 351 thrombocytopaenia and elevated fibrosis scores), and an increased risk of clinical 352 complications. A previous report from the same setting also documents elevated rates of severe 353 fibrosis in HBV monoinfected compared to their HBV/HIV coinfected counterparts [31], although 354 this observation is not consistent as another African study found elevated APRI scores in 355 patients with coinfection [4].

356

In our cohort, there was no difference in the prevalence of elevated hepatic transaminases (ALT and AST) between monoinfected and coinfected patient groups. It is important to observe that significant evidence of progressive liver disease can be present even in the absence of abnormalities in conventional 'liver function tests'. This highlights a need for clinical surveillance that is broader than any single serum marker.

363 The worse overall outcomes among the population with HBV monoinfection may stem from the 364 sustained neglect of HBV infection as a clinical and public health problem [18], relatively 365 complex algorithms for HBV treatment stratification, and less consistent and rigorous access to 366 tenofovir monotherapy [32]. HCC can arise independent of liver fibrosis [16], and therefore even 367 among HBV-infected individuals with no objective evidence of inflammatory or fibrotic liver 368 disease, there is a potential for the emergence of malignancy. Our data raise the hypothesis 369 that adults with HBV monoinfection may be coming to clinical care too late, underlining a pressing need for simplified, scalable approaches to HBV diagnosis as well as treatment [33]. 370

371

#### 372 HBV suppression on therapy

373 Despite the immunological defect associated with HIV infection and the higher prevalence of 374 HBeAg+ status in this group, HBV viraemia can be successfully suppressed in the majority of 375 coinfected patients using conventional TDF-based cART regimens. However, even on 376 appropriate antiviral therapy, over a quarter of patients still had detectable HBV viraemia. This 377 may be explained by sub-optimal adherence to therapy, pharmacokinetics (drug absorption, 378 levels within liver tissue), or drug resistance, and the long timeframes over which HBV viraemia 379 may decline on therapy [34]. Careful clinical surveillance is therefore important even in the 380 context of treatment, while there is a need for further studies to investigate TDF resistance [8].

381

#### 382 Changes to cART regimens with influence on HBV therapy

383 Changes to cART recommendations are developing, based on the success of dual therapy with 384 dolutegravir (DTG) regimens, both in the context of prior viraemic suppression [35] and for 385 salvage after failure of first-line treatment [36,37]. DTG/3TC is a common combination, but other 386 regimens do not contain any HBV active agents, (e.g. DTG combined with rilpivirine (RPV) [38], 387 emtricitabine (FTC) [39], or ritonavir-boosted lopinavir (LPVr) [37]). These regimens have not 388 yet been robustly evaluated in African populations, and are deemed inappropriate in the context 389 of HBV coinfection [40], although there are data demonstrating the efficacy of TDF/FTC in 390 mediating HBV suppression [41]. As dual therapy combinations enter clinical practice in Africa, 391 enhanced awareness and scrutiny will be critical to ensure that HBV-positive individuals are 392 diagnosed and treated with appropriate HBV-active agents, and that there is caution regarding 393 the potential for selection of HBV drug resistance on DTG/3TC treatment.

394

#### 395 Drug resistance

We identified a patient with phenotypic evidence of 3TC-resistant HBV in our cohort, congruent with evidence for the consistent selection of resistance among individuals on 3TC monotherapy [42], and in keeping with another African study that documented a high prevalence of 3TC resistance among coinfected patients [4]. Tenofovir resistance is less well substantiated, and can be difficult to confirm phenotypically due to the slow rate of HBV DNA suppression after institution of therapy [26]; however, there are reports confirming the potential for resistance to this agent (as previously reviewed [8]).

403

#### 404 Caveats and limitations

We have studied a small cohort, representing a distinct geographical setting and focusing on clinical care delivery within the specific environment of a tertiary care university hospital, which benefits from enhanced resource and infrastructure compared to many other healthcare settings. Even in this setting, missing data are problematic. Assessment with elastography is not consistently deployed, and serological markers are expensive, and not routinely undertaken at each clinic visit. Our small cohort may be underpowered to identify true associations, as reflected by borderline statistical significance of some of the relationships that we observe.

412

413 On the one hand, our study may be biased by the likelihood that patients with more advanced 414 pathology are most likely to be diagnosed and referred for tertiary-level follow-up; this could lead 415 to us over-estimating liver disease in those with HBV monoinfection. On the other hand, outside 416 this specific setting, the majority of cases of HBV monoinfection are undiagnosed, and those 417 with a diagnosis are less likely to be under routine surveillance, less likely to be stratified for 418 treatment, and less likely to receive a regular supply of appropriate therapy supported by clinical 419 monitoring; on these grounds, our cohort significantly under-represents the true burden of liver 420 disease. However, irrespective of the magnitude of the effect, head-to-head comparison of 421 comparable monoinfected and coinfected groups within this setting consistently suggest a 422 treatment advantage in the coinfected group, and a risk of continued emergence of liver 423 pathology among those with HBV monoinfection.

424

We have used platelet count as a marker of liver disease, but this is a non-specific approach, as thrombocytopaenia has diverse potential causes. The sensitivity and specificity of APRI and FIB-4 varies between settings, and further evaluation is specifically required in African populations [43]. We were unable to apply other fibrosis scores, such as gamma-

429 glutamyltranspeptidase-to-platelet ratio (GPR) [43,44], as the extended panel of liver function
430 tests required is not routinely collected.

431

We have taken a cross-sectional view, from which long-term outcomes can only be extrapolated
with caution. We have not been able to capture data regarding important influences on HBV and
HIV viral loads, including compliance with treatment and the presence of antiviral resistance.
HBV genotype data are not available for this cohort, but are known to have a role in disease
progression, and may add future insights [7,45].

437

#### 438 Conclusions

439 High standards of provision of HIV services, with consistent access to diagnosis, surveillance 440 and tenofovir-based treatment, are advantageous in delivering a high standard of clinical care 441 for those with HBV coinfection. The majority of HBV monoinfected patients remain undiagnosed, 442 but - even among those who know their status and are under follow-up - there remains a gap in 443 care provision, rendering them susceptible to long-term liver complications. In order to make 444 progress towards 2030 elimination goals, service providers should capitalise on the existing 445 infrastructure and investment deployed for HIV as both a precedent and a foundation for 446 improved clinical care for HBV infection.

447

#### 449 **FUNDING**

450 PCM and the OXSAHEP cohort are funded by Wellcome (grant ref 110110).

451

#### 452 ACKNOWLEDGEMENTS

We are grateful to the clinic and laboratory staff in infectious diseases, virology and gastroenterology at Tygerberg Hospital, Cape Town, and to the patients for their participation in this study.

456

#### 457 CONFLICTS OF INTEREST

458 Nil to declare

459

#### 461 **FIGURE LEGENDS**

462

Figure 1: Summary of cohort of 112 adults with HBV infection from Cape Town, South Africa, showing numbers with HBV monoinfection and HIV/HBV coinfection, those receiving therapy and those with suppressed viraemia. Viral load data were not available in 21 cases, of whom 13 were HBV monoinfected and 8 were HBV/HIV coinfected (shown in dashed lines and box). Green boxes indicate number with suppressed viraemia, yellow indicate number with one virus suppressed and the other detectable, red indicate number with no viraemic suppression.

470

471 Figure 2: Characteristics of adults with CHB, based on HBeAg status, HBV therapy and 472 virologic outcomes of therapy, comparing those with HBV monoinfection vs HBV/HIV 473 coinfection from a cross-sectional study in Cape Town, South Africa. A: Proportion of each 474 group testing HBeAg-positive. B: Proportion of monoinfected vs coinfected adults receiving 475 antiviral therapy: C: Proportion of monoinfected vs coinfected adults with HBV suppressed 476 below the limits of detection (<20 IU/ml) on antiviral therapy. D: HBV/HIV co-infected individuals 477 only, showing proportion who have suppressed HIV and/or HBV viral load on antiviral therapy. 478 In all cases, p-values calculated by Fisher's Exact Test, and the number of individuals 479 represented in each group is shown in brackets below the columns.

480

Figure 3: Assessment of liver disease in adults with HBV monoinfection vs HBV/HIV 481 482 coinfection in a cross-sectional study in Cape Town, South Africa based on serum 483 bilirubin and platelet count. BR - serum bilirubin: Plt - platelet count. Panels A and B: p-values 484 by Fisher's Exact Test comparing the number in each group falling above and below specified 485 thresholds (BR>17 mmol/L; moderate/severe thrombocytopaenia defined as plt <75 x  $10^3$ /µl). 486 Number in each group indicated in brackets under the columns; this varies according to data 487 availability. Panels C and D: p-values by Mann Whitney test; bars indicate median and IQR. C: 488 serum bilirubin levels are significantly elevated in the group with HBV monoinfection. D: 489 Distribution of plt highlights all of those with moderate/severe thrombocytopaenia (below dashed 490 line) are in HBV monoinfected group.

491

492 Figure 4: Assessment of liver disease using fibrosis scores derived from laboratory data 493 in adults with HBV monoinfection vs HBV/HIV coinfection in a cross-sectional study of 494 adults in Cape Town, South Africa. APRI - AST to Platelet Ratio Index; FIB-4 - Fibrosis-4 495 score (for formulae, see methods). Number in each group indicated in brackets under the 496 columns; this varies according to data availability. Panels A and B: p-values by Fisher's Exact 497 Test comparing the number in each group falling above and below the threshold for 498 cirrhosis/fibrosis (APRI >2; FIB-4 >3.25). Panels C and D: p-values by Mann Whitney test and 499 bars indicate median and IQR. No significant difference in median value for either score, but the 500 scatter plots show that individuals with scores above the threshold are predominantly in the 501 mono-infected group.

- 502
- 503

504 Table 1: Summary of clinical and laboratory parameters recorded from a cohort of 112

505 adults with HBV infection in Cape Town, South Africa, comparing groups with HBV

506 monoinfection (n=74) versus HIV/HBV coinfection (n=38). For extended version of table, see

507 Suppl data table 3.

	Whole Cohort	HBV monoinfection	HIV/HBV coinfection	p-value <sup>a</sup>
Sex M:F (% male)	62:50 (55%)	44:30 (59%)	18:20 (47%)	0.24
Median age in years at enrollment <sup>b</sup> (IQR)	44 (36-53)	46 (36-55)	41 (37-50)	0.28
Median body weight in kg <sup>c</sup> (IQR)	73 (60-85)	75 (60-87)	72 (59-80)	0.20
Proportion HBeAg positive <sup>d</sup> (%)	20/102 (19.6%)	8/67 (11.9%)	12/35 (34.3%)	0.009
Proportion with elevated ALT above ULN <sup>e</sup> (%)	49/109 (45%)	33/72 (46%)	16/37 (43%)	0.84
Proportion with elevated AST above ULN <sup>f</sup> (%)	27/85 (32%)	16/50 (32%)	11/35	1.0
Median BR <sup>g</sup> , mmol/L (IQR)	7 (5-13)	9 (5-15)	5 (4-9)	0.003
Proportion with elevated BR above ULN <sup>g</sup> (%)	14/95 (14.7%)	12/61 (19.7%)	2/34 (6.0%)	0.08
Median platelet count <sup>h</sup> , x10 <sup>3</sup> / ul (IQR)	226 (158-292)	227 (153-291)	249 (166-307)	0.38
Proportion with thrombocytopaenia <sup>h</sup> (%)	10/97 (10.3%)	10/62 (16%)	0/35 (0%)	0.01
Proportion with APRI score >2	8/79 (10%)	8/47 (17%)	0/32 (0%)	0.02
Proportion with FIB-4 score >3.25	12/78 (15%)	10/46 (22%)	2/32 (6%)	0.11
Proportion assessed by elastography (%)	38/112 (34%)	8/74 (11%)	30/38 (79%)	<0.0001*
Proportion with elastography score >9kPa (%)	7/38 (18%)	3/8 (38%)	4/30 (13%)	0.14

<sup>508</sup> 

IQR = inter-quartile range; ALT = alanine transferase; ULN = upper limit of normal. <sup>a</sup>p-value for categorical variables
 by Fisher's Exact Test, and for continuous variables by Mann Whitney test. <sup>b</sup>Age available for 111/112 individuals.
 <sup>c</sup>Body weight available for 108/112 individuals. <sup>d</sup>HBeAg status available for 102/112 individuals. <sup>e</sup>ALT available for
 60/62 males and 49/50 females, with ULN defined as 19 iu/ml for females and 30 iu/ml for males. <sup>f</sup>AST available for
 85/112 individuals, with ULN defined as 40 iu/ml. <sup>g</sup>BR available for 95/112 individuals; ULN defined as 17 mmol/L.

<sup>h</sup>Platelet count available for 97/112 individuals; moderate/severe thrombocytopaenia defined as platelet count <75</li>
 x10<sup>3</sup> / ul [26]. <sup>i</sup>CKD (chronic kidney disease) stages II and III defined as eGFR <90 ml/min/1.73m<sup>2</sup>. <sup>i</sup>Clinical complications reviewed for 108/112 individuals, defined as a documented diagnosis of HCC and/or cirrhosis.
 <sup>k</sup>Elastography data available for 38/112 individuals. \* Also significant by mutivariate analysis.

518

519 Table 2: Summary of antiviral therapy treatment and outcomes from a cohort of 112 520 adults with HBV infection in Cape Town, South Africa, comparing features of those with 521 HBV monoinfection (n=74) versus HIV/HBV coinfection (n=38).

	Whole Cohort	HBV monoinfection	HIV/HBV coinfection	p-value <sup>a</sup>
Proportion on antiviral treatment <sup>b</sup> (%)	71/108 (66%)	34/70 (49%)	37/38 (97)	<0.0001*
Median duration of therapy <sup>c</sup> , months (IQR)	31 (14-66)	29 (7-63)	37 (18-66)	0.1
Median HBV DNA viral load IU/ml <sup>d</sup> (range)	31 (0-1.7x10 <sup>8</sup> )	90 (0 - 1.7x10 <sup>8</sup> )	0 (0-1.0x10 <sup>8</sup> )	0.049
Proportion of HBV viraemia undetectable <sup>e</sup>	40/96 (42%)	20/61 (33%)	20/35 (57%)	0.03

522

<sup>a</sup>p-value for categorical variables by Fisher's Exact Test, and for continuous variables by Mann Whitney test.
 <sup>b</sup>Antiviral treatment data available for 108/112 individuals. <sup>c</sup>Duration of therapy defined for 29 HBV monoinfected and 27 HBV/HIV coinfected individuals. <sup>d</sup>HBV DNA viral load available for 61/74 HBV monoinfected and 35/38 HIV coinfected individuals. <sup>e</sup>Undetectable HBV DNA defined as viral load in serum below limit of detection of assay (typically HBV DNA <20 IU/ml). \* Also significant by mutivariate analysis.</li>

528

529

530

### 532 **SUPPLEMENTARY MATERIAL:**

533

536

534 **Suppl table 1: STROBE statement** (STrengthening the Reporting of OBservational studies in 535 Epidemiology) to support the quality of this observational cross-sectional study.

537 Suppl table 2: Raw data collected for 112 adults with chronic hepatitis B virus infection 538 recruited into a cross-sectional cohort in Cape Town, South Africa. These data are 539 available on-line: https://figshare.com/s/756eff7c317ef041cf0e. This link will be converted to a 540 permanent open access DOI (10.6084/m9.figshare.9649400) on acceptance of the paper for 541 publication.

542

543 Suppl table 3: Summary of parameters recorded from a cohort of 112 adults with HBV 544 infection in Cape Town, South Africa, comparing features of those with HBV 545 monoinfection (n=74) versus HIV/HBV coinfection (n=38). This is an extended version of 546 tables 1 and 2 presented in the main text.

547

548Suppl Fig 1: Ethnic origins (birth country) of participants enrolled into a cross-sectional549cohort of HBV infection in Cape Town, South Africa.

550

551 **Suppl Fig 2: Plasma viral loads for HBV and HIV in a cross-sectional study of adults in** 552 **Cape Town, South Africa.** (A) Distribution of HBV DNA viral load in individuals with HBV 553 monoinfection and HBV/HIV coinfection; horizontal lines indicate median with whiskers 554 representing IQR; the numbers shown in brackets under each category report the number of 555 individuals represented; p-values by Mann Whitney U test. (B) Relationship between HIV viral 556 load and HBV viral load in serum, with R<sup>2</sup> and p values by linear regression based on log<sub>10</sub> viral 557 load; note the point where HIV and HBV VL=0 represents 18 individuals.

#### 559 **REFERENCES**

- Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV
   coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol.
   2014;61: 20–33.
- Griggs D, Stafford-Smith M, Gaffney O, Rockstrom J, Ohman MC, Shyamsundar P, et al.
   Policy: Sustainable development goals for people and planet. Nature. 2013;495: 305–307.
- van Griensven J, Phirum L, Choun K, Thai S, De Weggheleire A, Lynen L. Hepatitis B and
   C co-infection among HIV-infected adults while on antiretroviral treatment: long-term
   survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia. PLoS One.
   2014;9: e88552.

Ndow G, Gore ML, Shimakawa Y, Suso P, Jatta A, Tamba S, et al. Hepatitis B testing and
 treatment in HIV patients in The Gambia-Compliance with international guidelines and
 clinical outcomes. PLoS One. 2017;12: e0179025.

- 572 5. Christian B, Fabian E, Macha I, Mpangala S, Thio CL, Ulenga N, et al. Hepatitis B virus
   573 coinfection is associated with high early mortality in HIV-infected Tanzanians on
   574 antiretroviral therapy. AIDS. 2019;33: 465–473.
- Matthews PC, Beloukas A, Malik A, Carlson JM, Jooste P, Ogwu A, et al. Prevalence and
   Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South
   Africa and Botswana. PLoS One. 2015;10: e0134037.
- McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, et al. Insights
   From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.
   Gastroenterology. 2018; doi:10.1053/j.gastro.2018.07.058
- Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti A-M, Goedhals D, et al. A
   systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A
   call for urgent action. PLoS Negl Trop Dis. 2018;12: e0006629.
- Park E-S, Lee AR, Kim DH, Lee J-H, Yoo J-J, Ahn SH, et al. Identification of a quadruple
   mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol.
   2019;70: 1093–1102.

- 587 10. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et
- al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med.
- 589 2015;373: 795–807.
- 590 11. 90-90-90: treatment for all [Internet]. [cited 7 Aug 2019]. Available:
- 591 https://www.unaids.org/en/resources/909090
- 592 12. HIV/AIDS Treatment Guidelines. In: AIDSinfo [Internet]. [cited 7 Aug 2019]. Available:
  593 https://aidsinfo.nih.gov/guidelines
- Meintjes G, Moorhouse MA, Carmona S, Davies N, Dlamini S, van Vuuren C, et al. Adult
  antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017;18: 776.
- 596 14. Overview | Hepatitis B (chronic): diagnosis and management | Guidance | NICE. Available:
  597 http://nice.org.uk/guidance/cg165
- 598 15. European Association for the Study of the Liver. Electronic address:
- easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017
- 600 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol.
  601 2017;67: 370–398.
- 602 16. Spearman CWN, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C, et
  603 al. South African guideline for the management of chronic hepatitis B: 2013. S Afr Med J.
  604 2013;103: 337–349.
- 605 17. Organization WH, Others. Combating hepatitis B and C to reach elimination by 2030:
  606 advocacy brief [Internet]. World Health Organization; 2016. Available:
- 607 https://apps.who.int/iris/bitstream/handle/10665/206453/WHO\_HIV\_2016.04\_eng.pdf
- 608 18. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B
  609 virus infection as a neglected tropical disease. PLoS Negl Trop Dis. 2017;11: e0005842.
- Aberra H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, et al. The WHO
  guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in
  Ethiopia. J Hepatol. 2019;70: 1065–1071.
- 613 20. Data Management and Workflow Software for Research LabKey. In: LabKey [Internet].
  614 [cited 22 Aug 2019]. Available: https://www.labkey.com/

615 21. Nice Clinical Guideline, Hepatitis B (chronic): diagnosis and management [Internet]. NICE
616 Clinical Guideline; 2013.

- Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a
  simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
  [Internet]. Hepatology. 2006. pp. 1317–1325. doi:10.1002/hep.21178
- 620 23. Lin Z-H, Xin Y-N, Dong Q-J, Wang Q, Jiang X-J, Zhan S-H, et al. Performance of the
- aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related
  fibrosis: An updated meta-analysis [Internet]. Hepatology. 2011. pp. 726–736.
  doi:10.1002/hep.24105
- 624 24. Chou R, Wasson N. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic
   625 Hepatitis C Virus Infection [Internet]. Annals of Internal Medicine. 2013. p. 807.
- 626 doi:10.7326/0003-4819-158-11-201306040-00005
- 25. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using
  standardized serum creatinine values in the modification of diet in renal disease study
  equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145: 247–254.
- 26. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al.
- Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48: 1000–1007.
- 632 27. Matthews P, Maponga T, Mofokeng M, Goedhals D. Hepatitis B virus (HBV) patient
  633 information leaflet [Internet]. 2019. doi:10.6084/m9.figshare.8969654.v1
- 634 28. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology.
  635 2009;49: S185–95.

636 29. McNaughton AL, Lourenço J, Hattingh L, Adland E, Daniels S, Van Zyl A, et al. HBV
637 vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical
638 cohort and dynamic model. BMC Med. 2019;17: 43.

- 30. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for
  global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16: 1399–1408.
- 31. Maponga TG, Andersson MI, van Rensburg CJ, Arends JE, Taljaard J, Preiser W, et al.
  HBV and HIV viral load but not microbial translocation or immune activation are associated

643 with liver fibrosis among patients in South Africa. BMC Infect Dis. 2018;18: 214.


- 32. Maponga TG, Nwankwo C, Matthews PC. Sustainable Development Goals for HBV
  elimination in South Africa: challenges, progress, and the road ahead. South African
  Gastroenterology Review. 2019;17: 15–25.
- 647 33. Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al.
- 648 Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology
- 649 Commission. Lancet Gastroenterol Hepatol. 2019;4: 135–184.
- 34. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of
  HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
- 652 PLoS One. 2013;8: e68152.


35. Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S. Virological efficacy of dual therapy
with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: longterm data from clinical practice. J Antimicrob Chemother. 2019; doi:10.1093/jac/dkz009


- 36. Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, et al.
  Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage
  regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials.
  2018;19: 242–248.
- 37. Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir
  versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor
  therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an
  open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19: 253–264.
- 38. Casado JL, Monsalvo M, Fontecha M, Vizcarra P, Rodriguez MA, Vivancos MJ, et al.
  Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected
  patients in a clinical setting. HIV Res Clin Pract. 2019;20: 64–72.
- 667 39. Diaco ND, Strickler C, Giezendanner S, Wirz SA, Tarr PE. Systematic De-escalation of
   668 Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus
- 669 Emtricitabine or Lamivudine in Swiss HIV-positive Persons. EClinicalMedicine. 2018;6: 21– 670 25.
- 40. Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-

672 1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert
673 Opin Pharmacother. 2018;19: 713–738.


- 41. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al. Patterns
  and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with
  HIV and hepatitis B virus. Clin Infect Dis. 2013;56: e87–94.
- 677 42. Gu L, Han Y, Li Y, Zhu T, Song X, Huang Y, et al. Emergence of Lamivudine-Resistant
  678 HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV
  679 and HBV in China. PLoS One. 2015;10: e0134539.
- 43. O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, et al. Liver
- 681 function tests and fibrosis scores in a rural population in Africa: estimation of the burden of
- disease and associated risk factors [Internet]. Gastroenterology. medRxiv; 2019.
- 683 doi:10.1101/19000968
- 44. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gammaglutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis
  in patients with chronic HBV infection in West Africa. Gut. 2016;65: 1369–1376.
- 45. Kramvis A. Molecular characteristics and clinical relevance of African genotypes and
  subgenotypes of hepatitis B virus. S Afr Med J. 2018;108: 17–21.













## В






### **HIV & HBV suppressed on therapy**






# Β

**BR** normal **BR** raised



D



•BR=17

